Geron (GERN) Expected to Announce Earnings on Wednesday

Geron (NASDAQ:GERN – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $55.3030 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Geron (NASDAQ:GERN – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The firm had revenue of $51.84 million during the quarter, compared to the consensus estimate of $50.59 million. On average, analysts expect Geron to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Get Geron alerts:

Geron Trading Down 2.0%

GERN stock opened at $1.45 on Wednesday. The firm has a fifty day moving average price of $1.32 and a 200 day moving average price of $1.46. Geron has a fifty-two week low of $1.04 and a fifty-two week high of $2.01. The firm has a market cap of $930.21 million, a PE ratio of -13.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78.

Institutional Trading of Geron

A number of institutional investors have recently bought and sold shares of GERN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Geron by 2.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after acquiring an additional 8,123 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Geron by 8.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company’s stock valued at $2,182,000 after acquiring an additional 104,840 shares during the period. Legal & General Group Plc lifted its holdings in shares of Geron by 8.3% in the 2nd quarter. Legal & General Group Plc now owns 550,871 shares of the biopharmaceutical company’s stock worth $775,000 after acquiring an additional 42,345 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Geron by 4.1% in the 2nd quarter. Rhumbline Advisers now owns 873,893 shares of the biopharmaceutical company’s stock worth $1,232,000 after acquiring an additional 34,437 shares during the last quarter. Finally, Prudential Financial Inc. boosted its stake in shares of Geron by 72.3% during the 2nd quarter. Prudential Financial Inc. now owns 79,494 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 33,352 shares during the period. 73.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Geron has an average rating of “Hold” and a consensus target price of $4.00.

Read Our Latest Research Report on Geron

Geron Company Profile

(Get Free Report)

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

Featured Stories

• Five stocks we like better than Geron
• D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
• Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
• These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
• Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.